8-K: Supernus Pharmaceuticals Reports Q2 2026 Results, Merges with Indivior

Supernus Pharmaceuticals announced strong Q2 2026 results with a 32% revenue increase and raised full-year guidance, alongside a significant all-stock merger of equals with Indivior Pharmaceuticals.

Summary

• Supernus Pharmaceuticals reported second quarter 2026 total revenues of $219.1 million, a 32% increase year-over-year.
• Revenues from the company's four growth products (Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO) increased by 52% to $175.7 million.
• The company is raising its full-year 2026 financial guidance.
• Supernus announced an agreement to merge with Indivior Pharmaceuticals, Inc. in an all-stock merger of equals.
• The company reported an operating loss of $58.0 million for Q2 2026, primarily due to a $54.9 million intangible asset impairment charge related to APOKYN.
• Adjusted operating earnings (non-GAAP) were $31.2 million for Q2 2026, down from $40.9 million in the prior year period.
• Net loss for Q2 2026 was $58.4 million, or $1.01 per diluted share, compared to net earnings of $22.5 million, or $0.40 per diluted share, in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong revenue growth and raised guidance, but tempered by a significant intangible asset impairment and the uncertainties inherent in a merger.

Positives

• Total revenues increased by 32% to $219.1 million in Q2 2026 compared to the same period last year.
• Combined revenues of the four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) increased by 52% to $175.7 million in Q2 2026.
• Net sales of Qelbree increased 15% to $89.2 million, driven by volume growth.
• Net sales of GOCOVRI increased 2% to $37.6 million, with prescription growth of 9%.
• ONAPGO net product sales were $13.5 million in Q2 2026, a 745% increase from the prior year.
• Collaboration revenue from ZURZUVAE was $35.4 million, representing 50% of net revenues, with U.S. sales up 53% and total prescriptions up 62%.
• The company is raising its full-year 2026 financial guidance.
• Cash, cash equivalents, and marketable securities stood at approximately $372.1 million as of June 30, 2026.

Negatives

• Operating loss was $58.0 million for Q2 2026, a significant shift from an operating gain of $12.1 million in Q2 2025.
• A non-cash intangible asset impairment charge of $54.9 million related to APOKYN was recorded in Q2 2026.
• Net loss for Q2 2026 was $58.4 million, compared to a net profit of $22.5 million in Q2 2025.
• Diluted loss per share was $1.01 in Q2 2026, compared to diluted earnings per share of $0.40 in Q2 2025.
• Net sales of Trokendi XR decreased 25% and Oxtellar XR decreased 25% in Q2 2026 compared to the prior year.
• Net sales of APOKYN decreased 51% in Q2 2026 compared to the prior year.

Risks

• The proposed merger with Indivior may not be completed in a timely manner or at all.
• Failure to obtain required approvals from Supernus' or Indivior's stockholders.
• Failure or delay in obtaining required regulatory approvals for the merger.
• The fixed exchange ratio for the all-stock merger will not be adjusted for changes in market prices of Supernus or Indivior shares.
• Business disruption resulting from the announcement or pendency of the transaction.
• Diversion of management's attention and resources from ongoing business operations.
• Difficulties and costs associated with integrating the two businesses.
• The risk that the anticipated benefits, synergies, and cost savings of the merger may not be realized.

Future Outlook

The company is raising its full-year 2026 financial guidance, projecting total revenues between $860 $890 million, combined R&D and SG&A expenses of $630 $660 million, an operating loss of $(20) $(50) million, and adjusted operating earnings (non-GAAP) of $150 $180 million. A regulatory submission for a second supplier for ONAPGO is on track for Q3 2026, with potential FDA approval by mid-year 2027.

Management Comments

• "Our first-half 2026 results reflect the continued strength and sustained momentum of our growth products and continued execution on our commercial strategy," said Jack Khattar, President and CEO of Supernus.
• "As we look to the remainder of the year, we remain focused on disciplined execution and prudent capital allocation, and we believe we are well positioned to build on this momentum."
• "We are excited about the future of Supernus, even more so following the recent agreement to merge with Indivior Pharmaceuticals, Inc. The combination of these two businesses will form a well-positioned CNS company with a unique profile of scale, growth, and flexibility to pursue additional business development opportunities."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in the CNS space, is characterized by significant R&D investment, regulatory hurdles, and a trend towards consolidation to achieve scale and broader market reach. The merger with Indivior aligns with this trend, aiming to create a more diversified and robust entity capable of competing effectively.

Comparison to Industry Standards

• The 32% year-over-year revenue growth in Q2 2026 is strong for the pharmaceutical sector, where growth rates can vary significantly by product lifecycle and therapeutic area.
• The 52% growth in key products indicates successful commercial execution and market penetration, often a benchmark for successful drug launches and lifecycle management.
• The significant intangible asset impairment charge ($54.9 million) is a notable event that can impact profitability metrics, though it is a non-cash charge and specific to the APOKYN asset.
• The decision to raise full-year guidance is a positive indicator, suggesting management confidence in continued performance, which is a key metric investors watch.
• The merger of equals with Indivior is a strategic move common in the industry to gain scale, diversify portfolios, and achieve cost synergies, a strategy employed by many mid-to-large cap biopharma companies.

Stakeholder Impact

• Shareholders: The merger of equals with Indivior creates a larger, potentially more diversified company, but the fixed exchange ratio means the value of the deal is subject to market fluctuations in both companies' stock prices prior to closing. The impairment charge and net loss may also be a concern.
• Employees: The merger will likely lead to integration efforts, potentially impacting roles and responsibilities. Management attention is noted as being diverted.
• Customers: Continued supply and access to Supernus' CNS treatments are expected, with ongoing development and regulatory submissions for products like ONAPGO.
• Suppliers and Business Partners: The merger may lead to changes in relationships and operational structures. The announcement and pendency of the transaction may make it more difficult to maintain these relationships.

Next Steps

• Supernus and Indivior will host a joint conference call and webcast presentation on August 3, 2026.
• Indivior intends to file a registration statement on Form S-4 with the SEC, which will include a joint proxy statement/prospectus.
• Supernus remains on track to submit a regulatory filing to the FDA for a second supplier for ONAPGO in the third quarter of 2026.
• The company expects to initiate a Phase 1 study for SPN-443 in the second half of 2026.
• Potential FDA approval for the second ONAPGO supplier by mid-year 2027.

Key Dates

Recommendation

The strong revenue growth and raised guidance are positive, but the significant intangible asset impairment, net loss, and the inherent uncertainties and integration challenges of a large merger of equals warrant a cautious approach. The fixed exchange ratio adds further risk. A 'hold' position allows investors to await further clarity on the merger's progress and the combined entity's performance.

Keywords

CNS diseases, pharmaceuticals, merger, financial results, revenue growth, Qelbree, GOCOVRI, ZURZUVAE